1
|
Mitsuhashi R, Song BS, Inoue K, Asano T, Noda S. Design and fabrication of a coupled high-Q photonic nanocavity system with large coupling coefficients. Opt Express 2024; 32:10630-10647. [PMID: 38571269 DOI: 10.1364/oe.513508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/16/2024] [Accepted: 02/27/2024] [Indexed: 04/05/2024]
Abstract
In a previous work, we demonstrated a coupled cavity system where photons in one storage cavity can be transferred to another storage cavity at an arbitrary time by applying a voltage pulse to a third cavity placed in a p-i-n junction. In this work, we demonstrate methods to improve the transfer efficiency and photon lifetimes of such a coupled system. Firstly, we designed a photonic-crystal structure that achieves a large coupling coefficient without reducing the radiation quality factor compared to the previously proposed structure: The photonic-crystal design was changed to a more symmetric configuration to suppress radiation losses and then optimized using an automatic structure tuning method based on the Covariance Matrix Adaptive Evolutional Strategy (CMAES). Here we added two improvements to achieve an evolution toward the desired direction in the two-dimensional target parameter space (spanned by the coupling coefficient and the inverse radiation loss). Secondly, to improve the experimental cavity quality factors, we developed a fabrication process that reduces the surface contamination associated with the fabrication of the p-i-n junction: We covered the photonic structure with a SiO2 mask to avoid the contamination and the electrode material was changed from Al to Au/Cr to enable cleaning by a weak acid. Owing to these improvements of the cavity design and the fabrication process, the obtained system provides coupling strengths that are about three times stronger and photon lifetimes that are about two times longer, compared to the previously reported system.
Collapse
|
2
|
Bartoli-Leonard F, Rogers M, Zheng K, Small A, Asano T, Kuraoka S, Blaser M, Natarajan P, Yeang C, Tsimikas S, O'donnell C, Aikawa M, Singh S, Stroes E, Aikawa E. Inhibition of novel lipoprotein(a) receptor major facilitator superfamily domain containing 5 (MFSD5) reduces development of aortic valve calcification. Cardiovasc Res 2022. [DOI: 10.1093/cvr/cvac066.139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: Other. Main funding source(s): Private grant from Kowa Pharmaceuticals to Brigham and Woman's Hospital
Calcific aortic valve stenosis (CAVS) is the most prevent valvular heart disease in the western world increasing exponentially with age, with an 112% increase in CAVS deaths in the last three decades; however no therapeutic treatment is currently available. Recently, lipoprotein(a) [Lp(a)] has been demonstrated to be an independent and causal risk factor for CAVS, yet the understanding of its cellular uptake and catabolism is limited thus underscoring the need for further investigation.
This study aimed to determine a target receptor, unique for Lp(a) on the surface of valvular interstitial cells (VICs) and ascertain the role of the receptor on the development of VIC calcification.
Unbiased ligand-receptor capture mass spectrometry (TriCEPS) was used to identify target receptor, with western blotting, ELISA, qPCR, alizarin red calcium staining and immunofluorescence used to validate the targets in vitro via siRNA inhibition and overexpression. Transmission electron microscopy (TEM) was used to determine uptake of Lp(a) within excised human valves. Identification of small molecule inhibitors was assessed computationally via the L1000 dataset, with the top hit candidate validated in vitro. Genotype-phenotype studies were examined using the United Kingdom Biobank (UKBB) and the Millions Veterans Program. Linear regression was used to evaluate association between aortic stenosis and plasma Lp(a) levels, and a phenotype-wide association analysis was then performed against this generated ‘genotype’.
Ligand-receptor capture mass spectrometry was used to detect novel membrane proteins with specific binding to Lp(a); MFSD5, MRC2, LDLR were identified as possible candidates. MFSD5 RNAscope demonstrated its presence in human aortic valves. Lp(a) uptake in VICs was confirmed via western blot and TEM. MFSD5 siRNA significantly reduced dil-labelled Lp(a) uptake in human VICs (p=0.003) and HEPG2 cells (p=0.0003), conversely MFSD5 overexpression increased uptake (p=0.0345, p=0.0318), whilst specificity of MFSD5 to Lp(a) alone was shown via no change in LDL uptake following MFSD5 inhibition (p=0.616, p=0.991). MFSD5 inhibition reduced RUNX2 (p=0.0124) and Osteocalcin (p<0.001) RNA expression and reduced alizarin red staining following culture in Lp(a) osteogenic media for 21 days (p<0.0033). Druggability of MFSD5 was confirmed by the L1000 database, which identified aminopurvalanol as a binding partner for MFSD5 and significantly reduced Lp(a) uptake within VICs (p=0.0091). MFSD5-loss of function within the UKBB showed no significant cardiovascular association, however 50kb +/- of the MFSD5 gene showed nominal association with hyperlipidaemia and atrial fibrillation.
The current study demonstrates the novel Lp(a) receptor MFSD5 may be responsible for uptake of Lp(a) within VICs, resulting in the development of aortic valve calcification, highlighting the need for further exploration into the role of MFSD5 in aortic valve disease.
Collapse
Affiliation(s)
- F Bartoli-Leonard
- Brigham And Women'S Hospital, Harvard Medical School , Boston , United States of America
| | - M Rogers
- Brigham And Women'S Hospital, Harvard Medical School , Boston , United States of America
| | - K Zheng
- Brigham And Women'S Hospital, Harvard Medical School , Boston , United States of America
| | - A Small
- Brigham And Women'S Hospital, Harvard Medical School , Boston , United States of America
| | - T Asano
- Brigham And Women'S Hospital, Harvard Medical School , Boston , United States of America
| | - S Kuraoka
- Brigham And Women'S Hospital, Harvard Medical School , Boston , United States of America
| | - M Blaser
- Brigham And Women'S Hospital, Harvard Medical School , Boston , United States of America
| | - P Natarajan
- Boston VA Healthcare System , Boston , United States of America
| | - C Yeang
- University of California, San Diego , San Diego , United States of America
| | - S Tsimikas
- University of California, San Diego , San Diego , United States of America
| | - C O'donnell
- Boston VA Healthcare System , Boston , United States of America
| | - M Aikawa
- Brigham And Women'S Hospital, Harvard Medical School , Boston , United States of America
| | - S Singh
- Brigham And Women'S Hospital, Harvard Medical School , Boston , United States of America
| | - E Stroes
- Amsterdam UMC - Location Academic Medical Center , Amsterdam , Netherlands (The)
| | - E Aikawa
- Brigham And Women'S Hospital, Harvard Medical School , Boston , United States of America
| |
Collapse
|
3
|
Isono M, Okubo K, Asano T, Sato A. Ataxia telangiectasia and Rad3-related inhibition by AZD6738 enhances gemcitabine-induced cytotoxic effects in bladder cancer cells. PLoS One 2022; 17:e0266476. [PMID: 35413091 PMCID: PMC9004738 DOI: 10.1371/journal.pone.0266476] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2021] [Accepted: 03/18/2022] [Indexed: 11/19/2022] Open
Abstract
The ataxia telangiectasia and rad3-related-checkpoint kinase 1 (ATR-CHK1) pathway is involved in DNA damage responses in many cancer cells. ATR inhibitors have been used in clinical trials in combination with radiation or chemotherapeutics; however, their effects against bladder cancer remain unclear. Here, the efficacy of combining gemcitabine with the novel ATR inhibitor AZD6738 was investigated in vitro in three bladder cancer cell lines (J82, T24, and UM-UC-3 cells). The effects of gemcitabine and AZD6738 on cell viability, clonogenicity, cell cycle, and apoptosis were examined. The combined use of gemcitabine and AZD6738 inhibited the viability and colony formation of bladder cancer cells compared to either treatment alone. Gemcitabine (5 nM) and AZD6738 (1 μM) inhibited cell cycle progression, causing cell accumulation in the S phase. Moreover, combined treatment enhanced cleaved poly[ADP-ribose]-polymerase expression alongside the number of annexin V-positive cells, indicating apoptosis induction. Mechanistic investigations showed that AZD6738 treatment inhibited the repair of gemcitabine-induced double-strand breaks by interfering with CHK1. Combining AZD6738 with gemcitabine could therefore be useful for bladder cancer therapy.
Collapse
Affiliation(s)
- Makoto Isono
- Department of Urology, National Defense Medical College, Tokorozawa, Japan
- * E-mail:
| | - Kazuki Okubo
- Department of Urology, National Defense Medical College, Tokorozawa, Japan
| | - Takako Asano
- Department of Urology, National Defense Medical College, Tokorozawa, Japan
| | - Akinori Sato
- Department of Urology, National Defense Medical College, Tokorozawa, Japan
| |
Collapse
|
4
|
Okubo K, REßING N, Schulz WA, Hansen FK, Asano T, Sato A. The Dual Histone Deacetylase-Proteasome Inhibitor RTS-V5 Acts Synergistically With Ritonavir to Induce Endoplasmic Reticulum Stress in Bladder Cancer Cells. Anticancer Res 2021; 41:5987-5996. [PMID: 34848452 DOI: 10.21873/anticanres.15417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2021] [Revised: 11/04/2021] [Accepted: 11/09/2021] [Indexed: 11/10/2022]
Abstract
BACKGROUND/AIM Simultaneous inhibition of histone deacetylase and proteasomes induces endoplasmic reticulum (ER) stress efficiently. RTS-V5 is the first dual histone deacetylase-proteasome inhibitor, and we anticipated that combining it with the cytochrome P450 family 3 subfamily A member 4 inhibitor ritonavir would enhance its activity in bladder cancer cells. MATERIALS AND METHODS Using bladder cancer cells (human T-24, J-82, murine MBT-2), we evaluated the ability and mechanism by which the combination of RTS-V5 and ritonavir induced ER stress and killed cancer cells. RESULTS The combination of RTS-V5 and ritonavir triggered robust apoptosis and inhibited bladder cancer growth effectively in vitro and in vivo. It caused ubiquitinated protein accumulation and induced ER stress synergistically. The combination inhibited the mammalian target of rapamycin pathway by increasing the expression of AMP-activated protein kinase. We also found that the combination caused histone and tubulin hyperacetylation. CONCLUSION Ritonavir enhances the ability of RTS-V5 to cause ER stress in bladder cancer cells.
Collapse
Affiliation(s)
- Kazuki Okubo
- Department of Urology, National Defense Medical College, Tokorozawa, Japan
| | - Nina REßING
- Pharmaceutical and Cell Biological Chemistry, Pharmaceutical Institute, University of Bonn, Bonn, Germany
| | - Wolfgang A Schulz
- Department of Urology, Medical Faculty, Heinrich Heine University, Duesseldorf, Germany
| | - Finn K Hansen
- Pharmaceutical and Cell Biological Chemistry, Pharmaceutical Institute, University of Bonn, Bonn, Germany
| | - Takako Asano
- Department of Urology, National Defense Medical College, Tokorozawa, Japan
| | - Akinori Sato
- Department of Urology, National Defense Medical College, Tokorozawa, Japan;
| |
Collapse
|
5
|
Abstract
After the accident at Fukushima Daiichi nuclear power plant on 11 March 2011, radioactive materials were released into the atmosphere resulting in environmental contamination. Following the implementation of environmental decontamination efforts, the Radiation Dose Registration Centre of the Radiation Effects Association established the radiation dose registration system for decontamination and related workers to consolidate and prevent the loss of radiation records. This article presents statistics on the radiation doses of decontamination and related workers using official records. Since approximately 10 years have passed since the accident in Fukushima, the types of work conducted in the affected restricted areas have changed over time. Therefore, changes in radiation dose for each type of work and comparisons with nuclear workers are presented.
Collapse
Affiliation(s)
- T Ogawa
- Radiation Effects Association, 1-9-16 Kaji-cho, Chiyoda-ku, Tokyo 101-0044, Japan
| | - T Ueno
- Radiation Effects Association, 1-9-16 Kaji-cho, Chiyoda-ku, Tokyo 101-0044, Japan
| | - T Asano
- Radiation Effects Association, 1-9-16 Kaji-cho, Chiyoda-ku, Tokyo 101-0044, Japan
| | - A Suzuki
- Radiation Effects Association, 1-9-16 Kaji-cho, Chiyoda-ku, Tokyo 101-0044, Japan
| | - A Ito
- Radiation Effects Association, 1-9-16 Kaji-cho, Chiyoda-ku, Tokyo 101-0044, Japan
| |
Collapse
|
6
|
Okubo K, Isono M, Asano T, REßING N, Schulz WA, Hansen FK, Sato A. Ubiquitin-proteasome System Is a Promising Target for Killing Cisplatin-resistant Bladder Cancer Cells. Anticancer Res 2021; 41:2901-2912. [PMID: 34083281 DOI: 10.21873/anticanres.15072] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2021] [Revised: 04/25/2021] [Accepted: 04/26/2021] [Indexed: 11/10/2022]
Abstract
BACKGROUND/AIM Activation of the ubiquitin-proteasome system (UPS) has been shown to be associated with drug resistance in cancer. Using bladder cancer cells, we investigated the association between UPS activation and cisplatin resistance and also the efficacy of UPS-targeting drugs. MATERIALS AND METHODS We established cisplatin-resistant bladder cancer cells (J82-cisR, T24-cisR) and examined the activation status of the UPS and the efficacy of MLN7243, oprozomib, ixazomib, and RTS-V5. RESULTS The UPS in cisplatin-resistant bladder cancer cells was activated compared to that in their parental controls. All the UPS-targeting drugs induced apoptosis and inhibited growth more effectively in the cisplatin-resistant bladder cancer cells than they did in the parental controls. Furthermore, these UPS-targeting drugs induced endoplasmic reticulum stress by causing unfolded protein accumulation at lower concentrations in the cisplatin-resistant bladder cancer cells. CONCLUSION Targeting the UPS could be an effective strategy for treating cisplatin-resistant bladder cancer.
Collapse
Affiliation(s)
- Kazuki Okubo
- Department of Urology, National Defense Medical College, Tokorozawa, Japan
| | - Makoto Isono
- Department of Urology, National Defense Medical College, Tokorozawa, Japan
| | - Takako Asano
- Department of Urology, National Defense Medical College, Tokorozawa, Japan
| | - Nina REßING
- Pharmaceutical and Cell Biological Chemistry, Pharmaceutical Institute, University of Bonn, Bonn, Germany
| | - Wolfgang A Schulz
- Department of Urology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany
| | - Finn K Hansen
- Pharmaceutical and Cell Biological Chemistry, Pharmaceutical Institute, University of Bonn, Bonn, Germany
| | - Akinori Sato
- Department of Urology, National Defense Medical College, Tokorozawa, Japan;
| |
Collapse
|
7
|
Okubo K, Miyai K, Kato K, Asano T, Sato A. Simvastatin-romidepsin combination kills bladder cancer cells synergistically. Transl Oncol 2021; 14:101154. [PMID: 34144348 PMCID: PMC8220249 DOI: 10.1016/j.tranon.2021.101154] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2021] [Revised: 05/26/2021] [Accepted: 06/09/2021] [Indexed: 12/25/2022] Open
Abstract
Simvastatin-romidepsin combination kills bladder cancer cells synergistically. The combination induces histone acetylation by activating AMPK. AMPK activation and histone acetylation are associated with ER stress induction. Positive feedback cycle between ER stress induction and PPARγ expression.
The HMG-CoA reductase inhibitor simvastatin activates AMP-activated protein kinase (AMPK) and thereby induces histone acetylation. We postulated that combining simvastatin with the histone deacetylase (HDAC) inhibitor romidepsin would kill bladder cancer cells by inducing histone acetylation cooperatively. The combination of romidepsin and simvastatin induced robust apoptosis and killed bladder cancer cells synergistically. In murine subcutaneous tumor models using MBT-2 cells, a 15-day treatment with 0.5 mg/kg romidepsin and 15 mg/kg simvastatin was well tolerated and inhibited tumor growth significantly. Mechanistically, the combination induced histone acetylation by activating AMPK. The combination also decreased the expression of HDACs, thus further promoting histone acetylation. This AMPK activation was essential for the combination's action because compound C, an AMPK inhibitor, suppressed the combination-induced histone acetylation and the combination's ability to induce apoptosis. We also found that the combination increased the expression of peroxisome proliferator-activated receptor (PPAR) γ, leading to reactive oxygen species production. Furthermore, the combination induced endoplasmic reticulum (ER) stress and this ER stress was shown to be associated with increased AMPK expression and histone acetylation, thus playing an important role in the combination's action. Our study also suggests there is a positive feedback cycle between ER stress induction and PPARγ expression.
Collapse
Affiliation(s)
- Kazuki Okubo
- Department of Urology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan
| | - Kosuke Miyai
- Department of Basic Pathology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan
| | - Kimi Kato
- Department of Basic Pathology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan
| | - Takako Asano
- Department of Urology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan
| | - Akinori Sato
- Department of Urology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan.
| |
Collapse
|
8
|
Isono M, Okubo K, Asano T, Sato A. Inhibition of checkpoint kinase 1 potentiates anticancer activity of gemcitabine in bladder cancer cells. Sci Rep 2021; 11:10181. [PMID: 33986399 PMCID: PMC8119486 DOI: 10.1038/s41598-021-89684-5] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2020] [Accepted: 04/26/2021] [Indexed: 12/13/2022] Open
Abstract
Checkpoint kinases (CHKs) are involved in the DNA damage response in many cancer cells. CHK inhibitors have been used in clinical trials in combination with chemotherapeutics; however, their effect against bladder cancer remains unclear. Here, we investigated the efficacy of combining gemcitabine with MK-8776, a novel CHK1 inhibitor, in four bladder cancer cell lines. The effects of gemcitabine and MK-8776 on cell viability, clonogenicity, cell cycle, and apoptosis were examined alongside in vivo efficacy using murine xenograft tumor models. Combined treatment inhibited the viability and colony formation of bladder cancer cells compared to either single treatment. Although gemcitabine (10 nM) alone increased the cell number in S-phase, it increased the cell number in sub-G1 phase when combined with MK-8776 (0.5 µM). Combined treatment enhanced cleaved poly[ADP-ribose]-polymerase expression alongside the number of annexin-V-positive cells, indicating the induction of apoptosis. In vivo, administration of gemcitabine and MK-8776 was well tolerated and suppressed tumor growth. Mechanistically, the combined treatment elevated γH2A.X and suppressed Rad51 expression. Our study demonstrates that MK-8776 and gemcitabine combined induces apoptosis and suppresses proliferation in bladder cancer cells by inhibiting CHKs and DNA repair. Therefore, CHK1 inhibition combined with gemcitabine may be a potential treatment for bladder cancer.
Collapse
Affiliation(s)
- Makoto Isono
- Department of Urology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan.
| | - Kazuki Okubo
- Department of Urology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan
| | - Takako Asano
- Department of Urology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan
| | - Akinori Sato
- Department of Urology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan
| |
Collapse
|
9
|
Sawazaki H, Ito K, Asano T, Kuroda K, Horiguchi A, Tsuda H, Asano T. Expressions of P-Glycoprotein, Multidrug Resistance Protein 1 and Annexin A2 as Predictive Factors for Intravesical Recurrence of Bladder Cancer after the Initial Transurethral Resection and Immediate Single Intravesical Instillation of Adriamycin. Asian Pac J Cancer Prev 2021; 22:1459-1466. [PMID: 34048174 PMCID: PMC8408374 DOI: 10.31557/apjcp.2021.22.5.1459] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2021] [Accepted: 05/07/2021] [Indexed: 12/02/2022] Open
Abstract
OBJECTIVE Immediate single instillation of chemotherapy following transurethral resection of bladder tumor (TURBT) is suggested for non-muscle invasive bladder cancer (NMIBC) patients. However, no study has evaluated molecular marker that was involved in intravesical recurrence (IVR) after single instillation of chemotherapy. Therefore, this study aimed to evaluate whether P-glycoprotein, multidrug resistance protein 1 (MRP1), Annexin A2 (ANXA2) or nucleophosmin (NPM) expression predicts IVR after initial TURBT and immediate single intravesical adriamycin instillation. METHODS We retrospectively reviewed consecutive 443 patients who underwent TURBT. Of these, 54 patients who underwent initial TURBT and single instillation of adriamycin for NMIBC were included. The expressions of P-glycoprotein, MRP1, ANXA2 and NPM were evaluated immunohistochemically and were divided into 2 groups (low or high) according to the staining intensity and/or proportion of positive cells. IVR was assessed by Kaplan-Meier method. Cox`s multivaritate analyses were performed to identify independent predictors for IVR. RESULTS Nineteen patients (35.1%) had IVR. High P-glycoprotein expression was significantly correlated with multiplicity, pT stage and high grade. High ANXA2 expression was significantly correlated with high grade. MRP1 and NPM were not correlated with any clinicopathological variables. MRP1 expression and ANXA2 expression were significantly correlated with P-glycoprotein expression. Patients with high P-glycoprotein expression had significantly worse IVR-free survival (IVRFS) than those with low P-glycoprotein expression (P =0.015). The difference in IVRFS rates between patients with high ANXA2 expression and those with low ANXA2 expression was nearly significant (P =0.057). Univariate analyses indicated multiplicity, high grade and high P-glycoprotein expression were significant predictors for IVR. Multivariate analysis indicated high grade was an independent predictor for IVR. CONCLUSIONS High P-glycoprotein expression was associated with IVR. Further study was needed to determine significance of P-glycoprotein expression in IVR after single intravesical adriamycin instillation.
Collapse
Affiliation(s)
- Harutake Sawazaki
- Department of Urology, National Defense Medical College Tokorozawa, Japan.
| | - Keiichi Ito
- Department of Urology, National Defense Medical College Tokorozawa, Japan.
| | - Takako Asano
- Department of Urology, National Defense Medical College Tokorozawa, Japan.
| | - Kenji Kuroda
- Department of Urology, National Defense Medical College Tokorozawa, Japan.
| | - Akio Horiguchi
- Department of Urology, National Defense Medical College Tokorozawa, Japan.
| | - Hitoshi Tsuda
- Department of Basic Pathology, National Defense Medical College Tokorozawa, Japan.
| | - Tomohiko Asano
- Department of Urology, National Defense Medical College Tokorozawa, Japan.
| |
Collapse
|
10
|
Onuki T, Shoji M, Kikuchi M, Asano T, Suzuki H, Tannno K, Shinke T. Clinical risk predictors for bradycardia, supraventricular tachycardia and epilepsy necessitating therapy in patients with unexplained syncope monitored by insertable cardiac monitor. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.0709] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Insertable cardiac monitors (ICMs) allow for lengthy monitoring of cardiac rhythm and improve diagnostic yield in patients with unexplained syncope. In most cardiac syncope cases, sick sinus syndrome, atrioventricular block, and paroxysmal supraventricular tachycardia (SVT) are detected using ICMs. On the other hand, epileptic seizures are sometimes diagnosed as unexplained syncope because in these situations, the loss of consciousness is a similar manifestation. Thus, the population of patients with unexplained syncope monitored by ICMs includes epileptic patients. Clinical risk factors for bradycardia, SVT and epilepsy that necessitate therapy in patients with unexplained syncope are not well known. If these risks can be clarified, clinicians could provide more specific targeted monitoring.
Purpose
We aimed to identify these predictors.
Methods
We retrospectively reviewed medical records of consecutive patients who received ICMs to monitor unexplained syncope in three medical facilities. We performed Cox's stepwise logistic regression analysis to identify significant independent risk factors for bradycardia, SVT, and epilepsy.
Results
One hundred thirty-two patients received ICMs to monitor unexplained syncope. During the 17-month follow-up period, 19 patients (10 patients had sick sinus syndrome and 9 had atrioventricular block) needed pacemaker for bradycardia; 8 patients (3 had atrial flutter, 4 had atrial tachycardia, and 1 had paroxysmal atrial fibrillation) needed catheter ablation for SVT; and 9 patients needed antiepileptic agents from the neurologist.Stepwise logistic regression analysis indicated that syncope during effort (odds ratio [OR] = 3.41; 95% confidence interval [CI], 1.21 to 9.6; p=0.02) was an independent risk factor for bradycardia. Palpitation before syncope (OR = 9.46; 95% CI, 1.78 to 50.10; p=0.008) and history of atrial fibrillation (OR = 10.1; 95% CI, 1.96 to 52.45; p=0.006) were identified as significant independent prognostic factors for SVT. Syncope while supine (OR = 11.7; 95% CI, 1.72 to 79.7; p=0.01) or driving (OR = 15.6; 95% CI, 2.10 to 115.3; p=0.007) was an independent factor for epileptic seizure.
Conclusions
ICMs are useful devices for diagnosing unexplained syncope. Palpitation, atrial fibrillation and syncope during effort were independent risk factors for bradycardia and for SVT. Syncope while supine or driving was an independent risk factor for epilepsy. We should carefully follow up of patients with these risk factors.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- T Onuki
- Showa University Hospital, Division of Cardiology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - M Shoji
- Showa University Hospital, Division of Cardiology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - M Kikuchi
- Cardiovascular Center, Showa University Koto Toyosu Hospital, Tokyo, Japan
| | - T Asano
- Division of Cardiology, Department of Medicine, Showa University Fujigaoka Hospital, Kanagawa, Japan
| | - H Suzuki
- Division of Cardiology, Department of Medicine, Showa University Fujigaoka Hospital, Kanagawa, Japan
| | - K Tannno
- Cardiovascular Center, Showa University Koto Toyosu Hospital, Tokyo, Japan
| | - T Shinke
- Showa University Hospital, Division of Cardiology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| |
Collapse
|
11
|
Asano T, Mitsuhashi Y, Yamashita J, Ito R, Saji M, Wakabayashi K, Yahagi K, Shinke T, Mase T, Miyachi H, Higuchi S, Miyauchi K, Yamamoto T, Nagao K, Takayama M. Relationship between age and the impact of revascularization on mortality in patients with non-ST-elevation myocardial infarction. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1766] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
It is known that the early coronary revascularization in patients with non-ST-elevation myocardial infarction (NSTEMI) was associated with favorable clinical outcomes. However, it is still unclear whether this efficacy is equivalent over all the ages of the patients.
Methods
Patients with NSTEMI were screened from the database of the Tokyo CCU network registry. Of those, the patients treated without revascularization (medical treatment) were matched with the patients receiving revascularization by propensity score matching. The probabilities of in-hospital death were calculated in the logistic regression model. In two subgroups stratified according to median of the age (elderly and non-elderly subgroups), the odds ratios of revascularization for in-hospital death were calculated.
Results
In the patients registered between 2013 and 2017, 4,851 patients with NSTEMI were identified. After the screening, 370 patients with medical treatment were matched with 370 patients treated with revascularization. The incidence of in-hospital death was significantly higher in the patients with medical treatment (20.3% vs 13.0%, P=0.01). The two probability curves of in-hospital death in patients with and without revascularization converged as age increased. In the elderly subgroup, the revascularization was not significantly associated with favorable outcome of mortality, whereas it had a significant impact on mortality in the non-elderly subgroup (odds ratio: 0.47 [95% CI 0.23–0.95]).
Conclusion
The impact of revascularization on short-term mortality in patients with NSTEMI tended to be reduced as age increased.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- T Asano
- Tokyo CCU Network, Tokyo, Japan
| | | | | | - R Ito
- Tokyo CCU Network, Tokyo, Japan
| | - M Saji
- Tokyo CCU Network, Tokyo, Japan
| | | | | | | | - T Mase
- Tokyo CCU Network, Tokyo, Japan
| | | | | | | | | | - K Nagao
- Tokyo CCU Network, Tokyo, Japan
| | | |
Collapse
|
12
|
Asano T, Mitsuhashi Y, Sachi M, Wakabayashi K, Yahagi K, Shinke T, Mase T, Miyachi H, Tujiguchi S, Yamashita J, Yamazaki M, Miyauchi K, Yamamoto T, Nagao K, Takayama M. The impact of low diastolic blood pressure on 30-day mortality of patients with acute myocardial infarction. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1652] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
It is known that low diastolic blood pressure (DBP) is associated with long-term cardiovascular events after acute myocardial infarction (AMI). However, the impact of low diastolic blood pressure on short-term outcome has not yet been well investigated.
Methods and results
We included 15,208 patients who were hospitalized for AMI and registered in the Tokyo CCU network registry between 2013 and 2016. Thirty-day in-hospital mortality rate was 4.8% (728/15,208). To assess the relationship between DBP at the time of admission and 30-day mortality non-linearly, spline regression model was applied with the stratification of the cohort according to tercile of systolic blood pressure (SBP, low:≤122 mmHg, intermediate:123–148 mmHg, high:≥149 mmHg) and J-curve phenomenon was observed in the low and high SBP groups. In multivariate logistic regression analysis, adjusted odds ratio of the lowest quintile of DBP (≤64 mmHg) was 1.65 (95% CI:1.02–2.66) in low SBP group and 4.55 (95% CI:1.72–12.00) in high SBP group.
Conclusion
Low DBP was associated with increased 30-day in-hospital mortality rate after AMI even in patients with high SBP.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- T Asano
- Tokyo CCU Network, Tokyo, Japan
| | | | - M Sachi
- Tokyo CCU Network, Tokyo, Japan
| | | | | | | | - T Mase
- Tokyo CCU Network, Tokyo, Japan
| | | | | | | | | | | | | | - K Nagao
- Tokyo CCU Network, Tokyo, Japan
| | | |
Collapse
|
13
|
Asano T, Ono M, Saito A, Kanie T, Takaoka T, Komiyama N. Twenty-year trends in clinical outcome of randomized controlled trial for coronary intervention: systematic review and meta-regression analysis of 46 randomized controlled trials. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1473] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Aim
The technology of percutaneous coronary intervention (PCI) has been developed after the advent of coronary stent. However, the impact of the technological development on clinical outcomes is still unclear, whereas a remarkable improvement of clinical outcomes after PCI has not been observed in the trials comparing to medical therapy or coronary bypass graft. The current analysis aims to investigate trends in clinical outcomes after PCI after the emargence of coronary stent, using the randomized controlled trials (RCTs) comparing coronary stents.
Methods and results
We performed a systematic review of RCTs investigating coronary stents in non-specific population (excluding the trials particularly enrolling diabetic or myocardial infarction etc.) conducted between 1996 and 2015 (publication between 1997 and 2019) with independent clinical event adjudication. The random-effect meta-regression analysis including 90 arms with 94,831 patients in 46 RCTs was performed investigating the 20-year trends in clinical outcomes such as death, cardiac death, myocardial infarction, target lesion revascularization (TLR) and stent thrombosis at one and five years after the index procedure. The sensitivity analysis was performed by limiting to 20 all comer trials. In the meta-regression analysis, we did not observe significant change in the incidences of cardiac death and myocardial infarction after PCI over 20 years (P values for cardiac death: 0.666 at one year, 0.256 at five years and P values for myocardial infarction: 0.121 at one year, 0.376 at five years; R2 for cardiac death: <0.01 at one year and five years and R2 for myocardial infarction: <0.01 at one year and five years), whereas the incidences of clinically indicated TLR (P value <0.001, R2 = 0.40 at one year, P value = 0.002, R2 = 0.22 at five years) and stent thrombosis were decreased steeply in the first decade and slightly in the second decade (P value = 0.040, R2 = 0.09 at one year; P value = 0.017, R2 = 0.17 at five year). The sencitivity analysis limiting all-comer population revealed the consistent results.
Conclusion
The development of PCI had an impact on the 20-year trends in TLR and ST, despite there were no trends in the cardiac death and myocardial infarction.
Trends in the incidence of the outcomes
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- T Asano
- St. Luke's International Hospital, Cardiology, Tokyo, Japan
| | - M Ono
- St. Luke's International Hospital, Cardiology, Tokyo, Japan
| | - A Saito
- St. Luke's International Hospital, Cardiology, Tokyo, Japan
| | - T Kanie
- St. Luke's International Hospital, Cardiology, Tokyo, Japan
| | - T Takaoka
- St. Luke's International Hospital, Cardiology, Tokyo, Japan
| | - N Komiyama
- St. Luke's International Hospital, Cardiology, Tokyo, Japan
| |
Collapse
|
14
|
Okubo K, Asano T, Sato A. Simvastatin augments anticancer activity of romidepsin in bladder cancer cells by causing AMP-activated protein kinase activation and histone acetylation. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)32620-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
15
|
Kuroda K, Asano T, Horiguchi A, Ito K. Effect of increased expression of both ras-related C3 botulinum toxin substrate 1 and p21-activated kinase 1 in patients with N0M0 upper urinary tract urothelial carcinoma and cancer-free surgical margins. Jpn J Clin Oncol 2020; 50:465-472. [PMID: 32134451 DOI: 10.1093/jjco/hyz155] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2019] [Accepted: 09/06/2019] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND As a member of the Rho small guanosine triphosphatase family, ras-related C3 botulinum toxin substrate 1 (RAC1) interacts with various specific effectors, and p21-activated kinase 1 (PAK1), which has a role in both carcinogenesis and cellular invasion, binds to RAC1, after which activated PAK1 regulates cellular functions. There have been few reports about the simultaneous analysis of RAC1 and its downstream effector PAK1 in upper urinary tract urothelial carcinoma (UTUC). We assessed the expressions of both RAC1 and PAK1 and evaluated their association with clinicopathological parameters. METHODS Immunohistochemical studies of RAC1 or PAK1 were performed with specimens from 104 patients with N0M0 UTUC and cancer-free surgical margins. Correlation of the positive expression of RAC1 or PAK1 or both with clinicopathological parameters was evaluated. RESULTS A hazard model showed that the presence of mixed histologic features and moderate or strong positive expression of both RAC1 and PAK1 were independent factors for shortened disease-specific survival time (Ps = 0.041 and 0.016, respectively), and another hazard model revealed that only moderate or strong positive expression of both RAC1 and PAK1 was an independent factor for shortened recurrence-free survival time in the multivariate analysis (P = 0.036). Neither moderate or strong positive expression of RAC1 alone nor moderate or strong positive expression of PAK1 alone was an independent factor for a worse rate of disease-specific or recurrence-free survival in multivariate analysis. CONCLUSIONS Patients with N0M0 UTUC, cancer-free surgical margins and moderate or strong positive expression of both RAC1 and PAK1 should be carefully monitored after surgery.
Collapse
Affiliation(s)
- Kenji Kuroda
- Department of Urology, National Defense Medical College, Tokorozawa, Saitama, Japan
| | - Takako Asano
- Department of Urology, National Defense Medical College, Tokorozawa, Saitama, Japan
| | - Akio Horiguchi
- Department of Urology, National Defense Medical College, Tokorozawa, Saitama, Japan
| | - Keiichi Ito
- Department of Urology, National Defense Medical College, Tokorozawa, Saitama, Japan
| |
Collapse
|
16
|
Honda M, Asano T, Takajo D, Takada K, Nakamura M, Sekinaka-Mitsui K, Wakamatsu H, Nonoyama S. Cytokine Analysis of Eosinophilic Ascites in Systemic Lupus Erythematosus. Indian J Pediatr 2020; 87:322. [PMID: 31713211 DOI: 10.1007/s12098-019-03092-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/27/2019] [Accepted: 09/25/2019] [Indexed: 12/17/2022]
Affiliation(s)
- Mamoru Honda
- Department of Pediatrics, National Defense Medical College, 3-2, Namiki, Tokorozawa, Saitama, Japan.
| | - Takako Asano
- Department of Pediatrics, National Defense Medical College, 3-2, Namiki, Tokorozawa, Saitama, Japan
| | - Daiji Takajo
- Department of Pediatrics, National Defense Medical College, 3-2, Namiki, Tokorozawa, Saitama, Japan
| | - Kosei Takada
- Department of Pediatrics, National Defense Medical College, 3-2, Namiki, Tokorozawa, Saitama, Japan
| | - Mari Nakamura
- Department of Pediatrics, National Defense Medical College, 3-2, Namiki, Tokorozawa, Saitama, Japan
| | - Kanako Sekinaka-Mitsui
- Department of Pediatrics, National Defense Medical College, 3-2, Namiki, Tokorozawa, Saitama, Japan
| | - Hajime Wakamatsu
- Department of Pediatrics, National Defense Medical College, 3-2, Namiki, Tokorozawa, Saitama, Japan
| | - Shigeaki Nonoyama
- Department of Pediatrics, National Defense Medical College, 3-2, Namiki, Tokorozawa, Saitama, Japan
| |
Collapse
|
17
|
Okubo K, Isono M, Miyai K, Asano T, Sato A. Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells. Cancer Sci 2019; 111:112-126. [PMID: 31675763 PMCID: PMC6942444 DOI: 10.1111/cas.14225] [Citation(s) in RCA: 29] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2019] [Revised: 10/18/2019] [Accepted: 10/24/2019] [Indexed: 12/19/2022] Open
Abstract
Drug repositioning is an emerging approach to developing novel cancer treatments. Vorinostat is a histone deacetylase inhibitor approved for cancer treatment, but it could attenuate its anticancer activity by activating the mTOR pathway. The HMG‐CoA reductase inhibitor fluvastatin reportedly activates the mTOR inhibitor AMP‐activated protein kinase (AMPK), and we thought that it would potentiate vorinostat's anticancer activity in renal cancer cells. The combination of vorinostat and fluvastatin induced robust apoptosis and inhibited renal cancer growth effectively both in vitro and in vivo. Vorinostat activated the mTOR pathway, as evidenced by the phosphorylation of ribosomal protein S6, and fluvastatin inhibited this phosphorylation by activating AMPK. Fluvastatin also enhanced vorinostat‐induced histone acetylation. Furthermore, the combination induced endoplasmic reticulum (ER) stress that was accompanied by aggresome formation. We also found that there was a positive feedback cycle among AMPK activation, histone acetylation, and ER stress induction. This is the first study to report the beneficial combined effect of vorinostat and fluvastatin in cancer cells.
Collapse
Affiliation(s)
- Kazuki Okubo
- Department of Urology, National Defense Medical College, Tokorozawa, Japan
| | - Makoto Isono
- Department of Urology, National Defense Medical College, Tokorozawa, Japan
| | - Kosuke Miyai
- Department of Basic Pathology, National Defense Medical College, Tokorozawa, Japan
| | - Takako Asano
- Department of Urology, National Defense Medical College, Tokorozawa, Japan
| | - Akinori Sato
- Department of Urology, National Defense Medical College, Tokorozawa, Japan
| |
Collapse
|
18
|
Shindo Y, Kuribara H, Matsuoka T, Futo S, Sawada C, Shono J, Akiyama H, Goda Y, Toyoda M, Hino A, Asano T, Hiramoto M, Iwaya A, Jeong SI, Kajiyama N, Kato H, Katsumoto H, Kim YM, Kwak HS, Ogawa M, Onozuka Y, Takubo K, Yamakawa H, Yamazaki F, Yoshida A, Yoshimura T. Validation of Real-Time PCR Analyses for Line-Specific Quantitation of Genetically Modified Maize and Soybean UsingNew Reference Molecules. J AOAC Int 2019. [DOI: 10.1093/jaoac/85.5.1119] [Citation(s) in RCA: 97] [Impact Index Per Article: 19.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
Novel analytical methods based on real-time quantitative polymerase chain reactions by use of new reference molecules were validated in interlaboratory studies for the quantitation of genetically modified (GM) maize and soy. More than 13 laboratories from Japan, Korea, and the United States participated in the studies. The interlaboratory studies included 2 separate stages: (1) measurement tests of coefficient values, the ratio of recombinant DNA (r-DNA) sequence, and endogenous DNA sequence in the seeds of GM maize and GM soy; and (2) blind tests with 6 pairs of maize and soy samples, including different levels of GM maize or GM soy. Test results showed that the methods are applicable to the specific quantitation of the 5 lines of GM maize and one line of GM soy. After statistical treatment to remove outliers, the repeatability and reproducibility of these methods at a level of 5.0% were <13.7 and 15.9%, respectively. The quantitation limits of the methods were 0.50% for Bt11, T25, and MON810, and 0.10% for GA21, Event176, and Roundup Ready soy. The results of blind tests showed that the numerical information obtained from these methods will contribute to practical analyses for labeling systems of GM crops.
Collapse
Affiliation(s)
- Yoichiro Shindo
- Fundamental Research Laboratory, Asahi Breweries Ltd., 1-1-21 Midori, Moriya, Kitasoma-gun, Ibaraki 302-0106, Japan
| | - Hideo Kuribara
- Center for Food Quality, Labeling and Consumer Services, 1-21-2 Kitabukuro, Saitama, Saitama 330-9731, Japan
| | - Takeshi Matsuoka
- Center for Food Quality, Labeling and Consumer Services, 1-21-2 Kitabukuro, Saitama, Saitama 330-9731, Japan
| | - Satoshi Futo
- FASMAC Co., Ltd., 5-1-3 Midorigaoka, Atsugi, Kanagawa 243-0041, Japan
| | - Chihiro Sawada
- Japan Frozen Foods Inspection Corp., Nishi-1 Koyo, Higashinada-ku, Kobe, Hyogo 658-0033, Japan
| | - Jinji Shono
- Somatech Center, House Foods Co., 1-4 Takanodai, Yotsukaido, Chiba 284-0033, Japan
| | - Hiroshi Akiyama
- National Institute of Health Sciences, Ministry of Health, Labour and Welfare, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan
| | - Yukihiro Goda
- National Institute of Health Sciences, Ministry of Health, Labour and Welfare, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan
| | - Masatake Toyoda
- National Institute of Health Sciences, Ministry of Health, Labour and Welfare, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan
| | - Akihiro Hino
- National Food Research Institute, 2-1-12 Kannondai, Tsukuba, Ibaraki 305-8642, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Dai Z, Asano T, Ohde S, Komiyama N. P1643An exploratory analysis for the optimal monitoring interval of N-terminal pro-B-type natriuretic peptide in patients with stable heart failure. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a potential biomarker for monitoring the status of heart failure. However, the optimal monitoring interval is unknown. This study aims to investigate minimal informative monitoring interval of NT-proBNP in patients with stable chronic heart failure.
Methods
In this retrospective open cohort study, adult patients followed up at a tertiary hospital for chronic heart failure with NT-proBNP measurements were included if they had been previously admitted due to acute heart failure and were free from readmission over 6 months after discharge. We analyzed NT-proBNP measured between 6 months after discharge and the timepoint of an alteration of medication regimen or readmission due to worsening of heart failure. To distinguish actual progression of the disease from biological variability and measurement error, the signal-to-noise ratio method was applied with a random-effects model. Stratified analysis was performed according to underlying risks.
Results
In this analysis, 368 patients were included with NT-proBNP measured between July 2009 and December 2017. The patients had 6.0 times of NT-proBNP measurements in median (interquartile range [IQR] 4.0–10.0) during the follow-up period (median 12.0 months [IQR 6.0–27.0]). In the estimates of the random-effects model, signal (i.e. actual progression of the disease) exceeded noise (i.e. biological variability and measurement error) at 8.1 months (95% confidence interval [CI]: 5.7–10.1) after the index measurement. In a subgroup analysis according to the AHEAD risk score, the minimal informative monitoring interval was shortened as the risk score increased (0–1 point: 12.3 months [95% CI: 10.3–14.5]; 2–3 points: 8.0 months [95% CI: 6.8–9.7]; 4–5 points: 3.3 months [95% CI: 3.0–3.8]; Figure).
Informative intervals stratified by risk
Conclusion
In patients with stable chronic heart failure, the overall minimal informative monitoring interval of NT-proBNP measurement was 8.1 months, which varies by underlying risk. The optimal monitoring interval could be lengthened especially for patients at lower risk.
Collapse
Affiliation(s)
- Z Dai
- St. Luke's International Hospital, Department of Cardiology, Tokyo, Japan
| | - T Asano
- St. Luke's International Hospital, Department of Cardiology, Tokyo, Japan
| | - S Ohde
- St. Luke's International University, Graduate School of Public Health, Tokyo, Japan
| | - N Komiyama
- St. Luke's International Hospital, Department of Cardiology, Tokyo, Japan
| |
Collapse
|
20
|
Arakawa T, Norimoto S, Iwakiri S, Asano T, Niimi Y. Cavity resonator for circularly polarized microwave irradiation mounted on a cryostat. Rev Sci Instrum 2019; 90:084707. [PMID: 31472660 DOI: 10.1063/1.5098846] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/04/2019] [Accepted: 08/07/2019] [Indexed: 06/10/2023]
Abstract
We have constructed a cylindrical cavity resonator with a hybrid coupler where circularly polarized microwaves can be irradiated to a sample. The polarity of the microwave can be switched by changing the input ports of the hybrid coupler. The cavity resonator is small enough to be mounted on a cryostat which enables us to change the sample temperature in a wide range. To demonstrate the performance of the cavity resonator mounted on a cryostat, Yttrium Iron Garnet (YIG) was used as a test sample. We succeeded in selectively exciting left and right circularly polarized modes with high polarization (>80%). We also evaluated the susceptibility tensor of YIG in the cryostat. The technique presented here would offer a new direction in the fields of spintronics and quantum information.
Collapse
Affiliation(s)
- T Arakawa
- Graduate School of Science, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - S Norimoto
- Graduate School of Science, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - S Iwakiri
- Graduate School of Science, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - T Asano
- Graduate School of Science, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - Y Niimi
- Graduate School of Science, Osaka University, Toyonaka, Osaka 560-0043, Japan
| |
Collapse
|
21
|
Okubo K, Isono M, Asano T, Sato A. Metformin Augments Panobinostat's Anti-Bladder Cancer Activity by Activating AMP-Activated Protein Kinase. Transl Oncol 2019; 12:669-682. [PMID: 30849634 PMCID: PMC6402380 DOI: 10.1016/j.tranon.2019.02.001] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2019] [Accepted: 02/11/2019] [Indexed: 02/09/2023] Open
Abstract
Panobinostat, a histone deacetylase inhibitor, induces histone acetylation and acts against cancer but attenuates its anticancer activity by activating the mammalian target of rapamycin (mTOR) pathway. AMP-activated protein kinase (AMPK) is a cellular energy sensor that reportedly inhibits the mTOR pathway. The antidiabetic drug metformin is also a potent AMPK activator and we investigated whether it augmented panobinostat's antineoplastic activity in bladder cancer cells (UMUC3, J82, T24 and MBT-2). Metformin enhanced panobinostat-induced apoptosis and the combination inhibited the growth of bladder cancer cells cooperatively in vitro and in vivo. As expected, metformin increased the phosphorylation of AMPK and decreased the panobinostat-caused phosphorylation of S6 ribosomal protein, thus inhibiting the panobinostat-activated mTOR pathway. The AMPK activation was shown to play a pivotal role in the combination's action because the AMPK inhibitor compound C attenuated the combination's anticancer activity. Furthermore, the AMPK activation by metformin enhanced panobinostat-induced histone and non-histone acetylation. This acetylation was especially remarkable in the proteins in the detergent-insoluble fraction, which would be expected if the combination also induced endoplasmic reticulum stress.
Collapse
Affiliation(s)
- Kazuki Okubo
- Department of Urology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan
| | - Makoto Isono
- Department of Urology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan
| | - Takako Asano
- Department of Urology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan
| | - Akinori Sato
- Department of Urology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan.
| |
Collapse
|
22
|
Isono M, Sato A, Asano T, Okubo K, Asano T. Evaluation of Therapeutic Potential of Phenoxodiol, a Novel Isoflavone Analog, in Renal Cancer Cells. Anticancer Res 2018; 38:5709-5716. [PMID: 30275191 DOI: 10.21873/anticanres.12908] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2018] [Revised: 08/19/2018] [Accepted: 08/24/2018] [Indexed: 11/10/2022]
Abstract
BACKGROUND/AIM In the present study, the antineoplastic activity and mechanism of action of phenoxodiol, a novel isoflavone analog, was investigated in renal cancer cells. MATERIALS AND METHODS A panel of renal cancer cells (769-P, 786-O, Caki-2) was treated with phenoxodiol in vitro, and the efficacy of treatment was evaluated. RESULTS MTS assay results showed that phenoxodiol decreased renal cancer viability in a dose-dependent manner. In addition, it inhibited colony formation significantly and perturbed the cell cycle. Treatment with phenoxodiol increased the number of annexin-V-positive cells as well as the expression of cleaved poly ADP ribose polymerase, demonstrating that phenoxodiol induced apoptosis in renal cancer cells. Phenoxodiol also inhibited Akt pathway via dephosphorylation of Akt. CONCLUSION Phenoxodiol inhibited Akt pathway and induced apoptosis of renal cancer cells. The present study provides a theoretical basis for future development of a novel therapy effective against renal cancer.
Collapse
Affiliation(s)
- Makoto Isono
- Department of Urology, National Defense Medical College, Tokorozawa, Japan
| | - Akinori Sato
- Department of Urology, National Defense Medical College, Tokorozawa, Japan
| | - Takako Asano
- Department of Urology, National Defense Medical College, Tokorozawa, Japan
| | - Kazuki Okubo
- Department of Urology, National Defense Medical College, Tokorozawa, Japan
| | - Tomohiko Asano
- Department of Urology, National Defense Medical College, Tokorozawa, Japan
| |
Collapse
|
23
|
Okubo K, Isono M, Asano T, Sato A. Panobinostat and Nelfinavir Inhibit Renal Cancer Growth by Inducing Endoplasmic Reticulum Stress. Anticancer Res 2018; 38:5615-5626. [PMID: 30275179 DOI: 10.21873/anticanres.12896] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2018] [Revised: 09/10/2018] [Accepted: 09/13/2018] [Indexed: 11/10/2022]
Abstract
BACKGROUND/AIM There is no curative treatment for patients with advanced renal cancer. We believed that the combination of the histone deacetylase inhibitor panobinostat and the human immunodeficiency virus protease inhibitor nelfinavir would kill renal cancer cells by inducing endoplasmic reticulum (ER) stress. MATERIALS AND METHODS Using renal cancer cells (769-P, 786-O, Caki-2), the ability of this combination to induce ER stress and its mechanism of action were investigated. RESULTS The combination of drugs induced apoptosis and inhibited cancer growth effectively both in vitro and in vivo. Mechanistically, the combination induced ER stress and histone acetylation cooperatively. ER stress induction was shown to play a pivotal role in the anticancer effect of the combination because the protein synthesis inhibitor cycloheximide significantly attenuated combination-induced apoptosis. Nelfinavir was also found to increase the expression of the mammalian target of rapamycin (mTOR) inhibitor AMP-activated protein kinase (AMPK) and inhibited the panobinostat-activated mTOR pathway. CONCLUSION Panobinostat and nelfinavir inhibit renal cancer growth by inducing ER stress.
Collapse
Affiliation(s)
- Kazuki Okubo
- Department of Urology, National Defense Medical College, Tokorozawa, Japan
| | - Makoto Isono
- Department of Urology, National Defense Medical College, Tokorozawa, Japan
| | - Takako Asano
- Department of Urology, National Defense Medical College, Tokorozawa, Japan
| | - Akinori Sato
- Department of Urology, National Defense Medical College, Tokorozawa, Japan
| |
Collapse
|
24
|
Modolo R, Collet C, Miyazaki Y, Chichareon P, Asano T, Katagiri Y, Tenekecioglu E, Walsh S, Lesiak M, Moreno R, Escaned J, Banning A, Onuma Y, Serruys PW. P2639Clinical outcomes with the state-of-the-art PCI for the treatment of bifurcation lesions: a sub-analysis of the SYNTAX II study. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p2639] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- R Modolo
- Academic Medical Center of Amsterdam, Department of Cardiology, Amsterdam, Netherlands
| | - C Collet
- Academic Medical Center of Amsterdam, Department of Cardiology, Amsterdam, Netherlands
| | - Y Miyazaki
- Erasmus Medical Center, Department of Cardiology, Rotterdam, Netherlands
| | - P Chichareon
- Academic Medical Center of Amsterdam, Department of Cardiology, Amsterdam, Netherlands
| | - T Asano
- Academic Medical Center of Amsterdam, Department of Cardiology, Amsterdam, Netherlands
| | - Y Katagiri
- Academic Medical Center of Amsterdam, Department of Cardiology, Amsterdam, Netherlands
| | - E Tenekecioglu
- Erasmus Medical Center, Department of Cardiology, Rotterdam, Netherlands
| | - S Walsh
- Belfast Health and Social Care Trust, Department of Cardiology, Belfast, United Kingdom
| | - M Lesiak
- Poznan University of Medical Sciences, Department of Cardiology, Poznan, Poland
| | - R Moreno
- University Hospital La Paz, Department of Cardiology, Madrid, Spain
| | - J Escaned
- Hospital Clinic San Carlos, Department of Cardiology, Madrid, Spain
| | - A Banning
- John Radcliffe Hospital, Department of Cardiology, Oxford, United Kingdom
| | - Y Onuma
- Erasmus Medical Center, Department of Cardiology, Rotterdam, Netherlands
| | - P W Serruys
- Imperial College London, Department of Cardiology, London, United Kingdom
| | | |
Collapse
|
25
|
Asano T, Onuma Y, Escaned J, Van Der Schaaf R, Van Geuns R, Piek J, Serruys P. P3627The assessment of microvascular resistance and conductance three years after the implantation of Absorb bioresorbable vascular scaffold and Xience metallic stent: ABSORB II pressure-velocity substudy. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p3627] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- T Asano
- Academic Medical Center of Amsterdam, Amsterdam, Netherlands
| | - Y Onuma
- Erasmus Medical Center, Rotterdam, Netherlands
| | - J Escaned
- Hospital Clinic San Carlos, Madrid, Spain
| | | | - R Van Geuns
- Erasmus Medical Center, Rotterdam, Netherlands
| | - J Piek
- Academic Medical Center of Amsterdam, Amsterdam, Netherlands
| | - P Serruys
- Imperial College London, London, United Kingdom
| |
Collapse
|
26
|
Asano T, Onuma Y, Collet C, Sabate M, Morice M, Chevalier B, Windecker S, Serruys P. P573Angiographic late lumen loss revisited: impact on target lesion revascularization and device thrombosis. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy564.p573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- T Asano
- Academic Medical Center of Amsterdam, Amsterdam, Netherlands
| | - Y Onuma
- Erasmus Medical Center, Rotterdam, Netherlands
| | - C Collet
- Academic Medical Center of Amsterdam, Amsterdam, Netherlands
| | - M Sabate
- Hospital Clinic de Barcelona, Barcelona, Spain
| | - M Morice
- Institut Cardiovasculaire Paris Sud, Paris, France
| | - B Chevalier
- Institut Cardiovasculaire Paris Sud, Paris, France
| | | | - P Serruys
- Imperial College London, London, United Kingdom
| |
Collapse
|
27
|
Chichareon P, Collet C, Tenekecioglu E, Asano T, Katagiri Y, Miyazaki Y, Modolo R, Takahashi K, Kogame N, Onuma Y, Serruys P. P5344Clinical outcomes after primary PCI using contemporary drug eluting stents: evidence from a network meta-analysis comprising 12,639 patients. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p5344] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- P Chichareon
- Academic Medical Center of Amsterdam, Amsterdam, Netherlands
| | - C Collet
- Academic Medical Center of Amsterdam, Amsterdam, Netherlands
| | - E Tenekecioglu
- Academic Medical Center of Amsterdam, Amsterdam, Netherlands
| | - T Asano
- Academic Medical Center of Amsterdam, Amsterdam, Netherlands
| | - Y Katagiri
- Academic Medical Center of Amsterdam, Amsterdam, Netherlands
| | - Y Miyazaki
- Erasmus Medical Center, Rotterdam, Netherlands
| | - R Modolo
- Academic Medical Center of Amsterdam, Amsterdam, Netherlands
| | - K Takahashi
- Academic Medical Center of Amsterdam, Amsterdam, Netherlands
| | - N Kogame
- Academic Medical Center of Amsterdam, Amsterdam, Netherlands
| | - Y Onuma
- Erasmus Medical Center, Rotterdam, Netherlands
| | - P Serruys
- Imperial College London, London, United Kingdom
| |
Collapse
|
28
|
Katagiri Y, Serruys PW, Tenekecioglu E, Asano T, Collet C, Miyazaki Y, Piek JJ, Wykrzykowska J, Chevalier B, Mintz G, Onuma Y. P6374Acute and long-term relocation of minimal lumen area after Absorb bioresorbable scaffold or Xience metallic stent implantation. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p6374] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Y Katagiri
- Academic Medical Center of Amsterdam, Department of Cardiology, Amsterdam, Netherlands
| | - P W Serruys
- Imperial College London, London, United Kingdom
| | | | - T Asano
- Academic Medical Center of Amsterdam, Department of Cardiology, Amsterdam, Netherlands
| | - C Collet
- Academic Medical Center of Amsterdam, Department of Cardiology, Amsterdam, Netherlands
| | - Y Miyazaki
- Erasmus Medical Center, Rotterdam, Netherlands
| | - J J Piek
- Academic Medical Center of Amsterdam, Department of Cardiology, Amsterdam, Netherlands
| | - J Wykrzykowska
- Academic Medical Center of Amsterdam, Department of Cardiology, Amsterdam, Netherlands
| | - B Chevalier
- Institut Hospitalier Jacques Cartier, Massy, France
| | - G Mintz
- Cardiovascular Research Foundation, New York, United States of America
| | - Y Onuma
- Erasmus Medical Center, Rotterdam, Netherlands
| |
Collapse
|
29
|
Asano T, Sato A, Okubo K, Isono M, Asano T. MP72-09 RITONAVIR AND IXAZOMIB INHIBIT RENAL CANCER GROWTH IN VITRO AND IN VIVO BY INDUCING ENDOPLASMIC RETICULUM STRESS SYNERGISTICALLY. J Urol 2018. [DOI: 10.1016/j.juro.2018.02.2293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
30
|
Tsujita Y, Horiguchi A, Tasaki S, Isono M, Asano T, Ito K, Asano T, Mayumi Y, Kushibiki T. STAT3 inhibition by WP1066 suppresses the growth and invasiveness of bladder cancer cells. Oncol Rep 2017; 38:2197-2204. [PMID: 28849140 DOI: 10.3892/or.2017.5902] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2017] [Accepted: 08/04/2017] [Indexed: 11/06/2022] Open
Abstract
Signal transducer and activator of transcription 3 (STAT3) regulates the expression of genes mediating cell survival, proliferation and angiogenesis and is aberrantly activated in various types of malignancies, including bladder cancer. We examined whether it could be a novel therapeutic target for bladder cancer using the STAT3 inhibitor WP1066. In T24 and UMUC-3 bladder cancer cells, 5 µM WP1066 prevented the phosphorylation of STAT3 and 2.5 µM WP1066 decreased cell survival and proliferation significantly (P<0.01). WP1066 also induced apoptosis accompanied by the suppression of the expression of Bcl-2 and Bcl-xL in T24 cells. Moreover, the covered area in a wound and the number of cells invading through a Matrigel chamber decreased significantly (P<0.01) when cells were treated with WP1066. The activities of MMP-2 and MMP-9 were also decreased by treatment with 10 µM WP1066. Our results revealed that using WP1066 to inhibit the STAT3 signaling pathway suppressed the viability and invasiveness of bladder cancer cells effectively and could be a novel therapeutic strategy against bladder cancer.
Collapse
Affiliation(s)
- Yujiro Tsujita
- Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan
| | - Akio Horiguchi
- Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan
| | - Shinsuke Tasaki
- Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan
| | - Makoto Isono
- Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan
| | - Takako Asano
- Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan
| | - Keiichi Ito
- Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan
| | - Tomohiko Asano
- Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan
| | - Yoshine Mayumi
- Department of Medical Engineering, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan
| | - Toshihiro Kushibiki
- Department of Medical Engineering, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan
| |
Collapse
|
31
|
Zeng Y, Zeng Y, Cavalcante R, Collet C, Tenekecioglu E, Sotomi Y, Miyazaki Y, Katagiri Y, Asano T, Abdelghani M, Nie S, Bourantas C, Bruining N, Onuma Y, Serruys P. P2398Coronary calcification as a mechanism of plaque media shrinkage a multimodality intracoronary imaging study. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p2398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
32
|
Tasaki S, Horiguchi A, Asano T, Ito K, Asano T, Asakura H. Docosahexaenoic acid inhibits the phosphorylation of STAT3 and the growth and invasion of renal cancer cells. Exp Ther Med 2017; 14:1146-1152. [PMID: 28810571 DOI: 10.3892/etm.2017.4616] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2015] [Accepted: 01/26/2017] [Indexed: 12/13/2022] Open
Abstract
Docosahexaenoic acid (DHA) has a variety of anti-tumor activities. The present study examined the anti-tumor activity of DHA in renal cancer cells and its underlying mechanisms of action. The effects of DHA on the viability and proliferation of the human renal cancer cell lines Caki-1 and 786-O were examined by an MTS assay and cell counting. In addition, cell cycle distribution and cell apoptosis were analyzed by flow cytometry and Annexin V staining, and modulation of cell mobility and invasiveness was assessed by wound healing and Matrigel invasion assays. Effects of DHA on intracellular signaling pathways were also analyzed by western blotting. It was observed that DHA significantly reduced the viability and proliferation of Caki-1 and 786-O cells (P<0.01). Specifically, there were increases in the sub-G1 and G2/M cell populations, as well as the percentages of cells exhibiting Annexin-positive and propidium-iodide-negative staining. In addition, the covered area in a wound and the number of cells invading through a Matrigel chamber decreased when Caki-1 or 786-O cells were treated with DHA. Phosphorylation of epidermal growth factor receptor was also upregulated following DHA treatment, while phosphorylation of signal transducer and activator of transcription 3 and Akt was downregulated. Collectively, these data suggest that DHA may be useful in the treatment of renal cell carcinoma.
Collapse
Affiliation(s)
- Shinsuke Tasaki
- Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan.,Department of Urology, Saitama Medical University, Moroyama, Saitama 350-0495, Japan
| | - Akio Horiguchi
- Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan
| | - Takako Asano
- Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan
| | - Keiichi Ito
- Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan
| | - Tomohiko Asano
- Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan
| | - Hirotaka Asakura
- Department of Urology, Saitama Medical University, Moroyama, Saitama 350-0495, Japan
| |
Collapse
|
33
|
Abstract
The human immunodeficiency virus (HIV) protease inhibitor nelfinavir acts against malignancies by inducing endoplasmic reticulum (ER) stress. The HIV protease inhibitor ritonavir, on the other hand, not only induces ER stress but also inhibits P-glycoprotein's pump activity and thereby enhances the effects of its substrate drugs. We therefore postulated that ritonavir in combination with nelfinavir would kill bladder cancer cells effectively by inducing ER stress cooperatively and also enhancing nelfinavir's effect. Nelfinavir was shown to be a P-glycoprotein substrate, and the combination of nelfinavir and ritonavir inhibited bladder cancer cell growth synergistically. It also suppressed colony formation significantly. The combination significantly increased the number of cells in the sub-G1 fraction and also the number of annexin V+ cells, confirming robust apoptosis induction. The combination induced ER stress synergistically, as evidenced by the increased expression of glucose-regulated protein 78, ER-resident protein 44, and endoplasmic oxidoreductin-1-like protein. It also increased the expression of the mammalian target of rapamycin (mTOR) inhibitor AMP-activated protein kinase and caused dephosphorylation of S6 ribosomal protein, demonstrating that the combination also inhibited the mTOR pathway. We also found that the combination enhanced histone acetylation synergistically by decreasing the expression of HDACs 1, 3, and 6.
Collapse
Affiliation(s)
- Akinori Sato
- Department of Urology, National Defense Medical College, Tokorozawa, Saitama, Japan
| | - Takako Asano
- Department of Urology, National Defense Medical College, Tokorozawa, Saitama, Japan
| | - Kazuki Okubo
- Department of Urology, National Defense Medical College, Tokorozawa, Saitama, Japan
| | - Makoto Isono
- Department of Urology, National Defense Medical College, Tokorozawa, Saitama, Japan
| | - Tomohiko Asano
- Department of Urology, National Defense Medical College, Tokorozawa, Saitama, Japan
| |
Collapse
|
34
|
Sato A, Asano T, Okubo K, Isono M, Asano T. Ritonavir and ixazomib kill bladder cancer cells by causing ubiquitinated protein accumulation. Cancer Sci 2017; 108:1194-1202. [PMID: 28342223 PMCID: PMC5480085 DOI: 10.1111/cas.13242] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2016] [Revised: 02/28/2017] [Accepted: 03/14/2017] [Indexed: 12/13/2022] Open
Abstract
There is no curative treatment for advanced bladder cancer. Causing ubiquitinated protein accumulation and endoplasmic reticulum stress is a novel approach to cancer treatment. The HIV protease inhibitor ritonavir has been reported to suppress heat shock protein 90 and increase the amount of unfolded proteins in the cell. If the proteasome functions normally, however, they are rapidly degraded. We postulated that the novel proteasome inhibitor ixazomib combined with ritonavir would kill bladder cancer cells effectively by inhibiting degradation of these unfolded proteins and thereby causing ubiquitinated proteins to accumulate. The combination of ritonavir and ixazomib induced drastic apoptosis and inhibited the growth of bladder cancer cells synergistically. The combination decreased the expression of cyclin D1 and cyclin‐dependent kinase 4, and increased the sub‐G1 fraction significantly. Mechanistically, the combination caused ubiquitinated protein accumulation and endoplasmic reticulum stress. The combination‐induced apoptosis was markedly attenuated by the protein synthesis inhibitor cycloheximide, suggesting that the accumulation of ubiquitinated proteins played an important role in the combination's antineoplastic activity. Furthermore, the combination induced histone acetylation cooperatively and the decreased expression of histone deacetylases was thought to be one mechanism of this histone acetylation. The present study provides a theoretical basis for future development of novel ubiquitinated‐protein‐accumulation‐based therapies effective against bladder cancer.
Collapse
Affiliation(s)
- Akinori Sato
- Department of Urology, National Defense Medical College, Tokorozawa, Japan
| | - Takako Asano
- Department of Urology, National Defense Medical College, Tokorozawa, Japan
| | - Kazuki Okubo
- Department of Urology, National Defense Medical College, Tokorozawa, Japan
| | - Makoto Isono
- Department of Urology, National Defense Medical College, Tokorozawa, Japan
| | - Tomohiko Asano
- Department of Urology, National Defense Medical College, Tokorozawa, Japan
| |
Collapse
|
35
|
Isono M, Sato A, Okubo K, Asano T, Asano T. Ritonavir Interacts With Belinostat to Cause Endoplasmic Reticulum Stress and Histone Acetylation in Renal Cancer Cells. Oncol Res 2017; 24:327-335. [PMID: 27712589 PMCID: PMC7838685 DOI: 10.3727/096504016x14666990347635] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
The histone deacetylase (HDAC) inhibitor belinostat increases the amount of unfolded proteins in cells by promoting the acetylation of heat shock protein 90 (HSP90), thereby disrupting its chaperone function. The human immunodeficiency virus protease inhibitor ritonavir, on the other hand, not only increases unfolded proteins by suppressing HSP90 but also acts as a proteasome inhibitor. We thought that belinostat and ritonavir together would induce endoplasmic reticulum (ER) stress and kill renal cancer cells effectively. The combination of belinostat and ritonavir induced drastic apoptosis and inhibited the growth of renal cancer cells synergistically. Mechanistically, the combination caused ER stress (evidenced by the increased expression of the ER stress markers) and also enhanced histone acetylation by decreasing the expression of HDACs. To our knowledge, this is the first study that showed a beneficial combined effect of belinostat and ritonavir in renal cancer cells, providing a framework for testing the combination in renal cancer patients.
Collapse
Affiliation(s)
- Makoto Isono
- Department of Urology, National Defense Medical College, Tokorozawa, Saitama, Japan
| | | | | | | | | |
Collapse
|
36
|
Isono M, Sato A, Asano T, Okubo K, Asano T. MP73-13 PHENOXODIOL, A NOVEL SOY ISOFLAVONE ANALOG, INHIBITS AKT PATHWAY AND INDUCES RENAL CANCER APOPTOSIS. J Urol 2017. [DOI: 10.1016/j.juro.2017.02.3358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
37
|
Sano T, Nagayasu S, Suzuki S, Iwashita M, Yamashita A, Shinjo T, Sanui T, Kushiyama A, Kanematsu T, Asano T, Nishimura F. Epicatechin downregulates adipose tissue CCL19 expression and thereby ameliorates diet-induced obesity and insulin resistance. Nutr Metab Cardiovasc Dis 2017; 27:249-259. [PMID: 28062181 DOI: 10.1016/j.numecd.2016.11.008] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/15/2016] [Revised: 11/05/2016] [Accepted: 11/11/2016] [Indexed: 11/20/2022]
Abstract
BACKGROUND AND AIMS Epicatechin (EC) intake has been suggested to be beneficial for the prevention of cardiovascular disorders, and it is well known that adipose tissue inflammation is one of the major risk factors for coronary heart diseases. The purpose of the present study was to determine the in vitro and in vivo effects of EC on adipose tissue inflammation and obesity. METHODS AND RESULTS DNA microarray analysis was performed to evaluate the effects of EC on gene expression in adipocytes co-cultured with bacterial endotoxin-stimulated macrophages. To determine the in vivo effects of the catechin, C57BL/6 mice were fed either a high-fat diet (HFD) or HFD combined with EC, and metabolic changes were observed EC suppressed the expression of many inflammatory genes in the adipocytes co-cultured with endotoxin-stimulated macrophages. Specifically, EC markedly suppressed chemokine (CC motif) ligand 19 (CCL19) expression. The target cell of EC appeared to macrophages. The in vivo study indicated that mice fed the EC-supplemented HFD were protected from diet-induced obesity and insulin resistance. Accordingly, the expression levels of genes associated with inflammation in adipose tissue and in the liver were downregulated in this group of mice. CONCLUSIONS EC exerts beneficial effects for the prevention of adipose tissue inflammation and insulin resistance. Since we previously reported that mice deficient in the CCL19 receptor were protected from diet-induced obesity and insulin resistance, it can be concluded that the beneficial effects of EC could be mediated, at least in part, by marked suppression of CCL19 expression.
Collapse
Affiliation(s)
- T Sano
- Section of Periodontology, Kyushu University Faculty of Dental Science, Fukuoka, Japan
| | - S Nagayasu
- Department of Dental Science for Health Promotion, Hiroshima University Institute of Biomedical and Health Sciences, Hiroshima, Japan
| | - S Suzuki
- Department of Dental Science for Health Promotion, Hiroshima University Institute of Biomedical and Health Sciences, Hiroshima, Japan
| | - M Iwashita
- Section of Periodontology, Kyushu University Faculty of Dental Science, Fukuoka, Japan
| | - A Yamashita
- Section of Periodontology, Kyushu University Faculty of Dental Science, Fukuoka, Japan
| | - T Shinjo
- Section of Periodontology, Kyushu University Faculty of Dental Science, Fukuoka, Japan
| | - T Sanui
- Section of Periodontology, Kyushu University Faculty of Dental Science, Fukuoka, Japan
| | - A Kushiyama
- Division of Metabolic Diseases, The Institute for Adult Diseases, Asahi Life Foundation, Tokyo, Japan
| | - T Kanematsu
- Department of Cellular and Molecular Pharmacology, Hiroshima University Institute of Biomedical and Health Sciences, Hiroshima, Japan
| | - T Asano
- Department of Biological Chemistry, Hiroshima University Institute of Biomedical and Health Sciences, Hiroshima, Japan
| | - F Nishimura
- Section of Periodontology, Kyushu University Faculty of Dental Science, Fukuoka, Japan.
| |
Collapse
|
38
|
Shitara K, Kuwabara A, Fisher CAJ, Ogawa T, Asano T, Kaneko Y, Omote A, Moriwake H. Effect of oxygen vacancy segregation in Au or Pt/oxide hetero-interfaces on electronic structures. RSC Adv 2017. [DOI: 10.1039/c7ra04804a] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
We investigated the effects of oxygen vacancy segregation on electronic structures in the vicinity of hetero-interfaces between noble metals (Au and Pt) and yttria stabilized zirconia by performing first-principles calculations and Bader analysis.
Collapse
Affiliation(s)
- K. Shitara
- Nanostructures Research Laboratory
- Japan Fine Ceramics Center
- Nagoya
- Japan
- Research and Services Division of Materials Data and Integrated System
| | - A. Kuwabara
- Nanostructures Research Laboratory
- Japan Fine Ceramics Center
- Nagoya
- Japan
- Research and Services Division of Materials Data and Integrated System
| | - C. A. J. Fisher
- Nanostructures Research Laboratory
- Japan Fine Ceramics Center
- Nagoya
- Japan
| | - T. Ogawa
- Nanostructures Research Laboratory
- Japan Fine Ceramics Center
- Nagoya
- Japan
| | - T. Asano
- Advanced Research Division
- Panasonic Corporation
- Kyoto
- Japan
| | - Y. Kaneko
- Advanced Research Division
- Panasonic Corporation
- Kyoto
- Japan
| | - A. Omote
- Advanced Research Division
- Panasonic Corporation
- Kyoto
- Japan
| | - H. Moriwake
- Nanostructures Research Laboratory
- Japan Fine Ceramics Center
- Nagoya
- Japan
- Research and Services Division of Materials Data and Integrated System
| |
Collapse
|
39
|
Sato A, Asano T, Isono M, Okubo K, Asano T. Ritonavir interacts with ixazomib synergistically to cause ubiquitinated protein accumulation and endoplasmic reticulum stress in bladder cancer cells. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)61435-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
40
|
Nakaseko K, Asano T. AB0784 A Study of Serum Electrolyte Levels after Denosumab Administration. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.1053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
41
|
Sato S, Asano T, Kobayashi H, Watanabe H, Ohira H. AB0572 Impact of Aging on The Clinical Features and Treatment of Anca Associated Vasculitis in The Elderly. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.3815] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
42
|
Tasaki S, Horiguchi A, Asano T, Kuroda K, Sato A, Asakuma J, Ito K, Asano T, Asakura H. Preoperative serum docosahexaenoic acid level predicts prognosis of renal cell carcinoma. Mol Clin Oncol 2016; 5:69-73. [PMID: 27330769 DOI: 10.3892/mco.2016.890] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2015] [Accepted: 04/15/2016] [Indexed: 12/30/2022] Open
Abstract
The recent discovery and clinical development of targeted agents have expanded treatment options in metastatic renal cell carcinoma (RCC). However, metastatic RCC remains a lethal disease. Complete response is rare and treatment with targeted agents eventually fails in the majority of the patients. Therefore, there is a need for developing a prognostic tool and a novel therapeutic agent for RCC to improve the follow-up strategy after surgical treatment. Clinical data, including patient characteristics, serum fatty acid profile, clinicopathological parameters and clinical outcome, were obtained from 112 patients with RCC prior to surgical treatment. Preoperative fatty acid levels were grouped according to patient characteristics, such as performance status, body mass index or pathological parameters, and were analyzed using the Mann-Whitney U test. Cancer-specific survival in the high and low docosahexaenoic acid (DHA) level groups were compared using the Kaplan-Meier method. Cox proportional hazards models were applied to determine the independent prognostic factors associated with shortened cancer-specific survival. The serum DHA level in patients with metastasis was significantly lower compared with that in patients without metastasis (P=0.047). Low serum DHA level, presence of metastasis and cachexia were independent predictors of shortened cancer-specific survival in a multivariate Cox proportional hazard model (P=0.033, hazard ratio = 4.43). Patients with a serum DHA level below the median value exhibited significantly shorter cancer-specific survival compared with those with a higher serum DHA level (P=0.008). Thus, according to our results, the preoperative serum DHA level may be able to predict the surgical outcome of RCC. However, this finding requires validation by large-scale prospective studies.
Collapse
Affiliation(s)
- Shinsuke Tasaki
- Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan; Department of Urology, Saitama Medical University, Iruma, Saitama 350-0495, Japan
| | - Akio Horiguchi
- Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan
| | - Takako Asano
- Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan
| | - Kenji Kuroda
- Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan
| | - Akinori Sato
- Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan
| | - Junichi Asakuma
- Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan
| | - Keiichi Ito
- Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan
| | - Tomohiko Asano
- Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan
| | - Hirotaka Asakura
- Department of Urology, Saitama Medical University, Iruma, Saitama 350-0495, Japan
| |
Collapse
|
43
|
Isono M, Sato A, Okubo K, Asano T, Ito K, Asano T. MP92-16 RITONAVIR AND DELANZOMIB INHIBIT RENAL CANCER GROWTH IN VITRO AND IN VIVO BY INDUCING ENDOPLASMIC RETICULUM STRESS SYNERGISTICALLY. J Urol 2016. [DOI: 10.1016/j.juro.2016.02.2649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
44
|
Inokuchi J, Kuroiwa K, Naito S, Kakehi Y, Sugimoto M, Tanikawa T, Fujimoto H, Gotoh M, Masumori N, Ogawa O, Etoh M, Ohyama C, Yamaguchi A, Matsuyama H, Ichikawa T, Asano T, Takenaka A, Fujimoto K, Yamaguchi R, Habuchi T, Hashine K, Arai Y, Nagaoka A, Nishiyama H, Shinohara N, Niwakawa M, Egawa S, Ozono S, Kawano Y, Ishizuka O, Nishimura K, Tochigi T, Sugimura Y, Mizusawa J, Eba J. 801 The impact of ureteral ligation on clinical outcome during radical nephroureterectomy for upper urinary tract urothelial carcinoma: Multi-institutional case series study JCOG1110A. ACTA ACUST UNITED AC 2016. [DOI: 10.1016/s1569-9056(16)60803-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
45
|
|
46
|
Asano T, Sato A, Isono M, Okubo K, Ito K, Asano T. Bortezomib and belinostat inhibit renal cancer growth synergistically by causing ubiquitinated protein accumulation and endoplasmic reticulum stress. Biomed Rep 2015; 3:797-801. [PMID: 26623018 DOI: 10.3892/br.2015.523] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2015] [Accepted: 09/15/2015] [Indexed: 01/07/2023] Open
Abstract
There is no curative treatment for advanced renal cancer, and a novel treatment approach is urgently required. Inducing ubiquitinated protein accumulation and endoplasmic reticulum (ER) stress has recently emerged as a new approach in the treatment of malignancies. In the present study, we hypothesized that the histone deacetylase inhibitor belinostat would increase the amount of unfolded proteins in cells by inhibiting heat-shock protein (HSP) 90, and that the proteasome inhibitor bortezomib would inhibit their degradation by inhibiting the proteasome, thus causing ubiquitinated protein accumulation and ER stress synergistically. The combination of bortezomib and belinostat induced significant increases in apoptosis and inhibited renal cancer growth synergistically (combination indexes <1). The combination also suppressed colony formation significantly (P<0.05). As co-treatment with the pan-caspase inhibitor Z-VAD-FMK changed the number of Annexin V-positive cells, this combination-induced apoptosis was considered caspase dependent. Mechanistically, the combination synergistically caused ubiquitinated proteins to accumulate and induced ER stress, as evidenced by the increased expression of glucose-regulated protein 78 and HSP70. To the best of our knowledge, this is the first study demonstrating the beneficial combined effect of bortezomib and belinostat in renal cancer cells. The study provides a basis for clinical studies with the combination in patients with advanced renal cancer.
Collapse
Affiliation(s)
- Takako Asano
- Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan
| | - Akinori Sato
- Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan
| | - Makoto Isono
- Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan
| | - Kazuki Okubo
- Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan
| | - Keiichi Ito
- Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan
| | - Tomohiko Asano
- Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan
| |
Collapse
|
47
|
Ito T, Kenmochi T, Nishikawa T, Maruyama M, Kusaka M, Sasaki H, Asano T, Matsubara H, Hoshinaga K. A novel screening test for detecting graft thrombosis after pancreatic transplantation using contrast-enhanced ultrasonography with sonazoid. Transplant Proc 2015; 46:1917-9. [PMID: 25131070 DOI: 10.1016/j.transproceed.2014.05.071] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Pancreatic graft thrombosis is the primary cause of nonimmunologic graft loss, with an incidence ranging from 5% to 15%. Therefore, developing a screening test to detect graft thrombosis after pancreatic transplantation is important. We created a screening test to assess graft thrombosis after pancreatic transplantation using contrast-enhanced ultrasonography (CEUS) with Sonazoid in addition to Doppler ultrasonography. A total of seven patients were examined using CEUS after undergoing pancreatic transplantation. All patients were observed to have a clear blood flow from the horizontal region to the peripheral region of the splenic vein in the pancreatic graft, and only one of the seven patients exhibited a blood flow in the horizontal portion of the splenic vein on Doppler ultrasonography performed immediately after pancreatic transplantation. Results from CEUS with Sonazoid showed the blood flow in the splenic vein and parenchyma of the pancreatic graft in detail, despite the slow and lateral blood flow in the splenic vein of the pancreatic graft immediately after transplantation.
Collapse
Affiliation(s)
- T Ito
- Department of Organ Transplant Surgery, Fujita Health University, School of Medicine, Aichi, Japan.
| | - T Kenmochi
- Department of Organ Transplant Surgery, Fujita Health University, School of Medicine, Aichi, Japan
| | - T Nishikawa
- Division of Liver Biliary Tract and Pancreas Disease, Fujita Health University, School of Medicine, Aichi, Japan
| | - M Maruyama
- Department of Surgery, National Hospital Organization, Chiba East Hospital, Chiba, Japan
| | - M Kusaka
- Department of Urology, Fujita Health University, School of Medicine, Aichi, Japan
| | - H Sasaki
- Department of Urology, Fujita Health University, School of Medicine, Aichi, Japan
| | - T Asano
- Department of Surgery, National Hospital Organization, Chiba East Hospital, Chiba, Japan
| | - H Matsubara
- Department of Frontier Surgery, Chiba University, Graduate School of Medicine, Chiba, Japan
| | - K Hoshinaga
- Department of Urology, Fujita Health University, School of Medicine, Aichi, Japan
| |
Collapse
|
48
|
Sawazaki H, Ito K, Asano T, Kuroda K, Sato A, Asakuma J, Horiguchi A, Seguchi K, Asano T. MP7-11 PROGNOSTIC IMPACT OF NUCLEOPHOSMIN/B23 EXPRESSION IN UPPER TRACT UROTHELIAL CARCINOMA (UTUC) IN PATIENTS UNDERGOING RADICAL NEPHROURETERECTOMY (RNU). J Urol 2015. [DOI: 10.1016/j.juro.2015.02.218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
49
|
Saigo K, Otsuki K, Hasegawa M, Maruyama M, Akutsu N, Aoyama H, Matsumoto I, Noguchi H, Asano T, Kitamura H. 329. The impact of gemcitabine plus S-1 combination therapy in patients with highly advanced or recurrent pancreatic and biliary tract cancers. Eur J Surg Oncol 2014. [DOI: 10.1016/j.ejso.2014.08.319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
50
|
Kuroda K, Asakuma J, Asano T, Horiguchi A, Isono M, Tsujita Y, Sato A, Seguchi K, Ito K, Asano T. Clinical significance of p21-activated kinase 1 expression level in patients with upper urinary tract urothelial carcinoma. Jpn J Clin Oncol 2014; 45:103-10. [DOI: 10.1093/jjco/hyu163] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|